Investigación

ENSAYOS
CLÍNICOS

0
  • Investigador en 180 ensayos clínicos nacionales e internacionales

PROYECTOS
FIS

0
  • 7 Proyectos FIS del Instituto de Salud Carlos III (los 5 últimos como IP)

PROYECTOS
PRIVADOS

0
  • 21 proyectos de Fundaciones privadas obtenidos en convocatorias competitivas

ARTÍCULOS INTERNACIONALES

0
  • 170 artículos internacionales con un factor de impacto total de 1226,08 y 4.006 citaciones. Factor H= 40 (2023)

ARTÍCULOS
NACIONALES

0
  • 45 artículos nacionales con un factor de impacto total de 101,21 Factor H= 40 (2023)

LIBROS Y
CAPÍTULOS

0
  • 38 libros y capítulos

ENSAYOS CLÍNICOS EN CURSO

Esclerosis Múltiple

  • An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis (ALITHIOS). Protocol COMB157G2399. Start year: 2018. Ongoing. PI Rafael Arroyo.

  • Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O’HAND). Protocol WA40404. Start year: 2018. Ongoing. PI Rafael Arroyo.

  • EVOLUTION.A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. Protocol MS200527ˍ0080. Start year: 2020. Ongoing. PI Rafael Arroyo.

  • MUSSETE A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (MUSSETE). Protocol BN42082. Start year: 2020. Ongoing. PI Rafael Arroyo.

  • GAVOTTE. A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (GAVOTTE). Protocol BN42083. Start year: 2020. Ongoing. PI Rafael Arroyo.

  • HERCULES. A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis (HERCULES). Protocol EFC16645. Start year 2020. Ongoing. PI Rafael Arroyo.

  • GEMINI. A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis (GEMINI 1). Protocol EFC16033. Start year: 2020. Ongoing.

  • PERSEUS. A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS). Protocol EFC16035. Start year: 2020. Ongoing. PI Rafael Arroyo.

  • FENTREPID. A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Patients With Primary Progressive Multiple Sclerosis (FENtrepid). Protocol GN41971. Start year: 2021. Ongoing. PI Rafael Arroyo.

  • FENHANCE. A phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in adult patients with relapsing multiple sclerosis. Protocol: GN41851. Start year: 2021 ongoing. PI Rafael Arroyo.

  • REMODEL.   A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib. Protocol CLOU064C12302. Start year: 2023. Ongoing. PI Rafael Arroyo.

Alzheimer

  • AHEAD: BAN2401-G000-303. A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial). Start year: 2021. Ongoing. PI Rafael Arroyo.

  • N6535-4730: “A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE). Start year: 2021. Ongoing PI Rafael Arroyo.

  • N6535-4725: “A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease” (EVOKE plus). Start year: 2021. Ongoing PI Rafael Arroyo.

  • Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Prospective, Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Moderate Alzheimer’s Disease. GEMVAX.  Start year: 2023. Ongoing PI Rafael Arroyo.

Parkinson

  • A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease (PROSEEK). Protocol CLR_18_06. Start year: 2020. Ongoing. IP Rafael Arroyo.

  • PADOVA. A phase IIb, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous Prasinezumab in participants with early Parkinson’s disease. Protocol: BN42358. Start: 2021. Ongoing. IP Rafael Arroyo.

  • An adaptive phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson’s Disease. Protocol ACI-7104-PD-2103:  Start: 2023. Ongoing. IP . Rafael Arroyo.

Ictus

  • A multicenter, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the secondary prevention of ischemic stroke in adult patients with an acute non-cardioembolic ischemic stroke or high-risk TIA (OCEANIC-Stroke). Protocol: 20604. Start: 2023. Ongoing. SI Rafael Arroyo.

ÚLTIMOS PROYECTOS DE INVESTIGACIÓN

  • TÍTULO DEL PROYECTO: Metabolitos de la microbiota intestinal como posibles biomarcadores de la Enfermedad de Parkinson. ENTIDAD FINANCIADORA: Fundación Mutua Madrileña Automovilística. DURACIÓN: desde: 2023 – hasta: 2026. CUANTÍA DE LA SUBVENCIÓN: 42.000 €. INVESTIGADOR PRINCIPAL: Dra. Teresa Maycas Cepeda
  • TÍTULO DEL PROYECTO: MicroRNAs como biomarcadores de diagnóstico y nuevas dianas terapéuticas en esclerosis múltiple. ENTIDAD FINANCIADORA: Fundación Mutua Madrileña Automovilística. DURACIÓN: desde: 2022 – hasta: 2024. CUANTÍA DE LA SUBVENCIÓN: 49.455 €. INVESTIGADOR PRINCIPAL: Dr. Ignacio Casanova Peño
  • TÍTULO DEL PROYECTO: Biomarcadores precoces en la enfermedad de Alzheimer. ENTIDAD FINANCIADORA: Fundación Mutua Madrileña Automovilística. DURACIÓN: desde: 2020 – hasta: 2023. CUANTÍA DE LA SUBVENCIÓN: 30.000 €. INVESTIGADOR PRINCIPAL: Dra. Rocío García Cobos
  • TÍTULO DEL PROYECTO: Estudio de los microRNAs de EBV, HHV-6A y HHV-6B presentes en exosomas aislados de plasma de pacientes con esclerosis múltiple: correlación con la actividad y progresión de la enfermedad. ENTIDAD FINANCIADORA: Fundación Ramón Areces. CÓDIGO DEL PROYECTO: CIVP18A3860. DURACIÓN: desde: 2018 – hasta: 2020. CUANTÍA DE LA SUBVENCIÓN: 90.617 €. INVESTIGADOR PRINCIPAL: Dr. Roberto Álvarez Lafuente
  • TÍTULO DEL PROYECTO: Vitamina D y deterioro cognitivo en la esclerosis múltiple. ENTIDAD FINANCIADORA: Fundación Mutua Madrileña Automovilística. DURACIÓN: desde: 2017 – hasta: 2019. CUANTÍA DE LA SUBVENCIÓN: 24.000 €. INVESTIGADOR PRINCIPAL: Dr. Ignacio Casanova Peño
  • TÍTULO DEL PROYECTO: REEM: Red Española de Esclerosis Múltiple. ENTIDAD FINANCIADORA: Instituto de Salud Carlos III. Subdirección General de Redes y Centros de Investigación Cooperativa. 2012. REFERENCIA DEL PROYECTO: RD16/0015/0013. ENTIDADES PARTICIPANTES: Asociación Sanitaria Virgen Macarena, Consejo Superior de Investigaciones Científicas, Fundación IMIM, Fundación Instituto de Inv. Dr. Josep Trueta, Fundación Instituto de Investigación Valle de Hebrón, Fundación Instituto Mediterráneo para el avance de la Biotecnología Sanitaria (IMABIS), Fundación Investigación Biomédica Hospital Clínico San Carlos, Fundación Investigación Biomédica Hospital Ramón y Cajal, Fundación Vasca de Innovación e Investigación Sanitarias, Hospital Clínico de Santiago, Fundación IDICHUS, Hospital Nacional de Parapléjicos, Hospital Son Dureta, IDIBAPS-Hospital Clinic, Instituto Aragonés de Ciencias de la Salud, Servicio Canario de Salud, Universidad del País Vasco, Universidad Politécnica de Cataluña, Universidad Pompeu Fabra, Hospital Universitario Quirónsalud Madrid. DURACIÓN: DESDE : Enero 2017  HASTA: Diciembre 2021. INVESTIGADOR PRINCIPAL: Dra. Luisa María Villar (coordinador de la Red)

ÚLTIMAS PUBLICACIONES INTERNACIONALES

  • Domínguez-Mozo MI, González-Suárez I, Villar LM, Costa-Frossard L, Villarrubia N, Aladro Y, Pilo B, Montalbán X, Comabella M, Casanova-Peño I, Martínez-Ginés ML, García-Domínguez JM, García-Martínez MÁ, Arroyo R, Álvarez-Lafuente R. Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response. Front Immunol. 2023 Sep 29; 14:1248182. DOI: 10.3389/fimmu.2023.1248182.
  • Fernández O, Montalban X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Mongay-Ochoa N, Moral E, Oreja-Guevara C, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Rodríguez-Antigüedad A. 15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II). Rev Neurol. 2023 Jul 16; 77(2):47-60. DOI: 10.33588/rn.7702.2023168.
  • Fernández O, Montalban X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Mongay-Ochoa N, Moral E, Oreja-Guevara C, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Rodríguez-Antigüedad A. 15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I). Rev Neurol. 2023 Jul 1; 77(1):19-30. DOI: 10.33588/rn.7701.2023167.
  • Wray S, Jacques F, Miller TA, Nicholas JA, Arroyo R, Travis L, Khatri B, Chirieac M, Gandhi R, Roesch N, Rodrigues A, Melas-Melt L, Rawlings AM, Hunter SF. Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study. Mult Scler J Exp Transl Clin. 2022 Nov 15; 8(4):20552173221135888. DOI: 10.1177/20552173221135888.
  • Domínguez-Mozo MI, García-Frontini Nieto MC, Gómez-Calcerrada MI, Pérez-Pérez S, García-Martínez MÁ, Villar LM, Villarrubia N, Costa-Frossard L, Arroyo R, Álvarez-Lafuente R. Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients. Biology (Basel). 2022 Nov 8; 11(11):1633. DOI: 10.3390/biology11111633.
  • Domínguez-Mozo MI, López-Lozano L, Pérez-Pérez S, García-Martínez Á, Torrejón MJ, Arroyo R, Álvarez-Lafuente R. Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study. Front Immunol. 2022 Sep 14; 13:991662. DOI: 10.3389/fimmu.2022.991662.
  • Villarejo-Galende A, García-Arcelay E, Piñol-Ripoll G, Del Olmo-Rodríguez A, Viñuela F, Boada M, Franco-Macías E, Ibáñez de la Peña A, Riverol M, Puig-Pijoan A, Abizanda-Soler P, Arroyo R, Baquero-Toledo M, Feria-Vilar I, Balasa M, Berbel Á, Rodríguez-Rodríguez E, Vieira-Campos A, García-Ribas G, Rodrigo-Herrero S, Terrancle Á, Prefasi D, Lleó A, Maurino J. Quality of Life and the Experience of Living with Early-Stage Alzheimer’s Disease. J Alzheimers Dis. 2022; 90(2):719-726. DOI: 10.3233/JAD-220696.
  • Muñoz Ú, Sebal C, Escudero E, Urcelay E, Arroyo R, García-Martínez MA, Quintana FJ, Álvarez-Lafuente R, Sádaba MC. Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β. Sci Rep. 2022 Aug 3;12(1):13357. DOI: 10.1038/s41598-022-16218-y.
  • Villarejo-Galende A, García-Arcelay E, Piñol-Ripoll G, Del Olmo-Rodríguez A, Viñuela F, Boada M, Franco-Macías E, de la Peña AI, Riverol M, Puig-Pijoan A, Abizanda-Soler P, Arroyo R, Baquero-Toledo M, Feria-Vilar I, Balasa M, Berbel Á, Rodríguez-Rodríguez E, Vieira-Campos A, García-Ribas G, Rodrigo-Herrero S, Lleó A, Maurino J. Awareness of Diagnosis in Persons with Early-Stage Alzheimer’s Disease: An Observational Study in Spain. Neurol Ther. 2022 Sep;11(3):1183-1192. DOI: 10.1007/s40120-022-00367-3.
  • Muñoz Ú, Sebal C, Escudero E, García Sánchez MI, Urcelay E, Jayo A, Arroyo R, García-Martínez MA, Álvarez-Lafuente R, Sádaba MC. High prevalence of intrathecal IgA synthesis in multiple sclerosis patients. Sci Rep. 2022 Mar 11;12(1):4247. DOI: 10.1038/s41598-022-08099-y.
  • Pérez-Pérez S, Domínguez-Mozo MI, García-Martínez MÁ, Ballester-González R, Nieto-Gañán I, Arroyo R, Álvarez-Lafuente R. Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression. Biomedicines. 2022 Feb 5;10(2):387. DOI: 10.3390/biomedicines10020387.
  • Aliaga-Gaspar P, Hurtado-Guerrero I, Ciano-Petersen NL, Urbaneja P, Brichette-Mieg I, Reyes V, Rodríguez-Bada JL, Álvarez-Lafuente R, Arroyo R, Quintana E, Ramió-Torrentà L, Alonso A, Leyva L, Fernández O, Oliver-Martos B. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment. Front Immunol. 2021 Dec 16; 12:778204. DOI: 10.3389/fimmu.2021.778204.
  • Pérez-Pérez S, Domínguez-Mozo MI, García-Martínez MÁ, García-Frontini MC, Villarrubia N, Costa-Frossard L, Villar LM, Arroyo R, Álvarez-Lafuente R. Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression. Front Immunol. 2021 Nov 29; 12:798003. DOI: 10.3389/fimmu.2021.798003.
  • Fernández O, Montalban X, Aladro Y, Alonso A, Arroyo R, Calles C, Castillo-Triviño T, Comabella M, Costa-Frossard L, Forero L, Ginestal R, Landete L, Llaneza M, Llufriu S, Martínez-Ginés ML, Meca-Lallana J, Mendibe M, Oreja-Guevara C, Oterino A, Prieto JM, Ramió-Torrentà L, Romero-Pinel L, Téllez N, Rodríguez-Antigüedad A. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (II). Rev Neurol. 2021 Jun 16; 72(12):433-442. DOI: 10.33588/rn.7212.2021173.
  • Fernández O, Montalban X, Aladro Y, Alonso A, Arroyo R, Calles C, Castillo-Triviño T, Comabella M, Costa-Frossard L, Forero L, Ginestal R, Landete L, Llaneza M, Llufriu S, Martínez-Ginés ML, Meca-Lallana J, Mendibe M, Oreja-Guevara C, Oterino A, Prieto JM, Ramió-Torrentà L, Romero-Pinel L, Téllez N, Rodríguez-Antigüedad A. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (I). Rev Neurol. 2021 Jun 1; 72(11):397-406. DOI: 10.33588/rn.7211.2021172.
  • Pérez-Pérez S, Cuello JP, Martínez-Ginés M, Pardo-Rodríguez B, García-Domínguez JM, Domínguez-Mozo MI, Lozano-Ros A, García-Martínez MÁ, Higueras Y, Meldaña-Rivera A, Goicochea-Briceño H, Tejeda-Velarde A, Fernández-Velasco JI, Medina S, Arroyo R, Villar LM, Álvarez-Lafuente R. Evolution of antibody titres against Epstein-Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients. Sci Rep. 2021 Apr 19; 11(1):8441. DOI: 10.1038/s41598-021-87941-1.
  • Maycas-Cepeda T, López-Ruiz P, Feliz-Feliz C, Gómez-Vicente L, García-Cobos R, Arroyo R, García-Ruiz PJ. Hypomimia in Parkinson’s Disease: What Is It Telling Us? Front Neurol. 2021 Jan 25; 11:603582. DOI: 10.3389/fneur.2020.603582.
  • Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintoré M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord. 2021 Apr; 49:102717. DOI: 10.1016/j.msard.2020.102717.
  • Dominguez-Mozo MI, Perez-Perez S, Villarrubia N, Costa-Frossard L, Fernandez-Velasco JI, Ortega-Madueño I, Garcia-Martinez MA, Garcia-Calvo E, Estevez H, Luque Garcia JL, Torrejón MJ, Arroyo R, Villar LM, Alvarez-Lafuente R. Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. Cells. 2021 Jan 10;10(1):119. DOI: 10.3390/cells10010119.
  • Toboso I, Tejeda-Velarde A, Álvarez-Lafuente R, Arroyo R, Hegen H, Deisenhammer F, Sainz de la Maza S, Álvarez-Cermeño JC, Izquierdo G, Paramo D, Oliva P, Casanova B, Agüera-Morales E, Franciotta D, Gastaldi M, Fernández O, Urbaneja P, García-Domínguez JM, Romero F, Laroni A, Uccelli A, Perez-Sempere A, Saiz A, Blanco Y, Galimberti D, Scarpini E, Espejo C, Montalban X, Rasche L, Paul F, González I, Álvarez E, Ramo C, Caminero AB, Aladro Y, Calles C, Eguía P, Belenguer-Benavides A, Ramió-Torrentà L, Quintana E, Martínez-Rodríguez JE, Oterino A, López de Silanes C, Casanova LI, Landete L, Frederiksen J, Bsteh G, Mulero P, Comabella M, Hernández MA, Espiño M, Prieto JM, Pérez D, Otano M, Padilla F, García-Merino JA, Navarro L, Muriel A, Frossard LC, Villar LM. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. Front Neurol. 2020 Dec 17; 11:579438.
  •  Pérez-Pérez S, Domínguez-Mozo MI, Alonso-Gómez A, Medina S, Villarrubia N, Fernández-Velasco JI, García-Martínez MÁ, García-Calvo E, Estévez H, Costa-Frossard L, Álvarez-Cermeño JC, Luque-García JL, Arroyo R, Villar LM, Álvarez-Lafuente R. Acetate correlates with disability and immune response in multiple sclerosis. PeerJ. 2020 Nov 16;8: e10220. DOI: 10.7717/peerj.10220.
  • Domínguez-Mozo MI, Nieto-Guerrero A, Pérez-Pérez S, García-Martínez MÁ, Arroyo R, Álvarez-Lafuente R. MicroRNAs of Human Herpesvirus 6A and 6B in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Front Immunol. 2020 Sep 18; 11:2142. DOI: 10.3389/fimmu.2020.02142.
  • Bertolotto A, Arroyo R, Celius EG, Comi G, Havrdova EK, Honeycutt WD, Hunter SF, Izquierdo G, Kornek B, Miller T, Mitsikostas DD, Singer BA, Ziemssen T, Chung L, Daizadeh N, Afsar S, Hashemi L, Senior P. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. Neurol Ther. 2020 May 14. DOI: 10.1007/s40120-020-00191-7. Online ahead of print.
  • Domínguez-Mozo MI, Pérez-Pérez S, Villar LM, Oliver-Martos B, Villarrubia N, Matesanz F, Costa-Frossard L, Pinto-Medel MJ, García-Sánchez MI, Ortega-Madueño I, López-Lozano L, García-Martinez A, Izquierdo G, Fernández Ó, Álvarez-Cermeño JC, Arroyo R, Álvarez-Lafuente R. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Sci Rep. 2020 Aug 28;10(1):14244. DOI: 10.1038/s41598-020-71283-5.
  • Fernández O, Aladro Y, Arroyo R, Brieva L, Calles-Hernández MC, Carrascal P, Comabella M, Costa-Frossard L, Eichau S, García-Merino JA, Ginestal R, González I, Izquierdo G, Martínez-Ginés ML, Meca-Lallana JE, Mendibe-Bilbao MM, Oterino A, Prieto JM, Río J, Ramió-Torrentà L, Romero-Pinel L, Téllez N, Rodríguez-Antigüedad A. 12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II). Rev Neurol. 2020 Jun 1;70(11):417-42 9.
  • Fernández O, Aladro Y, Arroyo R, Brieva L, Calles-Hernández MC, Carrascal P, Comabella M, Costa-Frossard L, Eichau S, García-Merino JA, Ginestal R, González I, Izquierdo G, Martínez-Ginés ML, Meca-Lallana JE, Mendibe-Bilbao MM, Oterino A, Prieto JM, Río J, Ramió-Torrentà L, Romero-Pinel L, Téllez N, Rodríguez-Antigüedad A. 12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (I). Rev Neurol. 2020 May 16; 70(10):379-390.
  • Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology. 2020 May 5; 94(18): e1950-e1960.
  • García-Montojo M, Rodríguez-Martin E, Ramos-Mozo P, et al. Syncytin-1/HERV-W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patients [published online ahead of print, 2020 Feb 3]. Eur J Immunol. 2020;10.1002/eji.201948423.
  • Pérez-Pérez S, Eguia Del Rio P, Domínguez-Mozo MI, et al. Epidemiology of multiple sclerosis and vitamin D levels in Lanzarote, Canary Islands, Spain. PeerJ. 2019;7: e8235. Published 2019 Dec 18.
  • Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(9):845–856.
  • Arroyo R, Bury DP, Guo JD, et al. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis [published online ahead of print, 2019 May 30]. Mult Scler. 2019.
  • Fernández O, Tintoré M, Saiz A, et al. Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II). Revisión de las novedades presentadas en el Congreso ECTRIMS 2018: XI Reunión Post-ECTRIMS (II). Rev Neurol. 2019;68(11):468–479.
  • Fernández O, Tintore M, Saiz A, et al. Revision de las novedades presentadas en el congreso ECTRIMS 2018: XI Reunion Post-ECTRIMS (I) [Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (I)]. Rev Neurol. 2019;68(10):431–441.
  • Medina S, Sainz de la Maza S, Villarrubia N, et al. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Ann Clin Transl Neurol. 2019;6(2):355–363. Published 2019 Jan 15.
  • Gil-Varea E, Urcelay E, Vilariño-Güell C, Costa C, Midaglia L, Matesanz F, Rodríguez-Antigüedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, García-Merino JA, Ramió-Torrentà L, Triviño JC, Quintana E, Robles R, Sánchez-López A, Arroyo R, Alvarez-Cermeño JC, Vidal-Jordana A, Malhotra S, Fissolo N, Montalban X, Comabella M. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. J Neuroinflammation. 2018 Sep 14; 15(1):265.
  • Fernández O, Tintoré M, Saiz A, Calles-Hernández MC, Comabella M, Ramio-Torrenta L, Oterino A, Izquierdo G, Tellez N, García-Merino JA, Brieva L, Arnal-García C, Aladro Y, Mendibe-Bilbao MM, Meca-Lallana JE, Romero-Pinel L, Ginestal R, Martínez-Ginés ML, Arroyo R, Rodríguez-Antigüedad A. Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (I). Rev Neurol. 2018 Jul 1;67(1):15-27.
  • Fernández O, Tintoré M, Saiz A, Calles-Hernández MC, Comabella M, Ramio-Torrenta L, Oterino A, Izquierdo G, Téllez N, García-Merino JA, Brieva L, Arnal-García C, Aladro Y, Mendibe-Bilbao MM, Meca-Lallana JE, Romero-Pinel L, Ginestal R, Martínez-Gines ML, Arroyo R, Rodríguez-Antigüedad A. Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (II). Rev Neurol. 2018 Jul 15;67(2):50-62.
  • Pérez-Pérez S, Domínguez-Mozo MI, García-Martínez MÁ, Aladro Y, Martínez-Ginés M, García-Domínguez JM, López de Silanes C, Casanova I, Ortega-Madueño I, López-Lozano L, Torrejón MJ, Arroyo R, Álvarez-Lafuente R. Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis. Eur J Neurol. 2018 Dec; 25(12):1446-1453.
  • Alari-Pahissa E, Moreira A, Zabalza A, Álvarez-Lafuente R, Munteis E, Vera A, Arroyo R, Álvarez-Cermeño JC, Villar LM, López-Botet M, Martínez-Rodríguez JE. Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the ‘hygiene hypothesis’? Eur J Neurol. 2018 Jul; 25(7):925-933.

  • Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. PMID: 32757523. Factor de impacto: 74.699.
  • Arroyo R, Bury DP, Guo JD, et al. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis. Mult Scler. 2020 Jul;26(8):955-963. doi: 10.1177/1352458519849796. PMID: 31144568. Factor de impacto: 5.412.
  • Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. PMID: 33222767. Factor de Impacto: 30.039.
  • Bertolotto A, Arroyo R, Celius EG, Comi G, Havrdova EK, Honeycutt WD, Hunter SF, Izquierdo G, Kornek B, Miller T, Mitsikostas DD, Singer BA, Ziemssen T, Chung L, Daizadeh N, Afsar S, Hashemi L, Senior P. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. Neurol Ther. 2020 Dec; 9(2):443-457. doi: 10.1007/s40120-020-00191-7. PMID: 32410147. Factor de impacto: 3.650.
  • Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintoré M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord. 2020 Dec 24;49:102717. doi: 10.1016/j.msard.2020.102717. PMID: 33476880. Factor de impacto: 2.889.
  • Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology. 2020 May 5;94(18):e1950-e1960. PMID: 32300060. Factor de impacto: 8.770.
  • Dominguez-Mozo MI, Perez-Perez S, Villar LM, Oliver-Martos B, Villarrubia N, Matesanz F, Costa-Frossard L, Pinto-Medel MJ, García-Sánchez MI, Ortega-Madueño I, Lopez-Lozano L, Garcia-Martinez A, Izquierdo G, Fernández Ó, Álvarez-Cermeño JC, Arroyo R, Alvarez-Lafuente R. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Sci Rep. 2020 Aug 28;10(1):14244. doi: 10.1038/s41598-020-71283-5. PMID: 32859922. Factor de impacto: 3.998.

  • Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. PMID: 29576505. Factor de impacto: 60.392
  • Alari-Pahissa E, Moreira A, Zabalza A, Alvarez-Lafuente R, Munteis E, Vera A, Arroyo R, Alvarez-Cermeño JC, Villar LM, López-Botet M, Martínez-Rodríguez JE. Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the ‘hygiene hypothesis’? Eur J Neurol. 2018 Jul;25(7):925-933. PMID: 29528545. Factor de impacto: 4.516.
  • Pérez-Pérez S, Domínguez-Mozo MI, García-Martínez MÁ, Aladro Y, Martínez-Ginés M, García-Domínguez JM, López de Silanes C, Casanova I, Ortega-Madueño I, López-Lozano L, Torrejón MJ, Arroyo R, Álvarez-Lafuente R. Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis. Eur J Neurol. 2018 Dec;25(12):1446-1453. PMID: 29996002. Factor de impacto: 4.516.
  • Gil-Varea E, Urcelay E, Vilariño-Güell C, Costa C, Midaglia L, Matesanz F, Rodríguez-Antigüedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, García-Merino JA, Ramió-Torrentà L, Triviño JC, Quintana E, Robles R, Sánchez-López A, Arroyo R, Alvarez-Cermeño JC, Vidal-Jordana A, Malhotra S, Fissolo N, Montalban X, Comabella M. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. J Neuroinflammation. 2018 Sep 14;15(1):265. PMID: 30217166. Factor de impacto: 5.793.
  • Arroyo González R. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. Expert Rev Neurother. 2018 Oct;18(10):785-791. doi: 10.1080/14737175.2018.1510772. PMID: 30235965. Factor de impacto: 3.743.
  • Medina S, Sainz de la Maza S, Villarrubia N, et al. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Ann Clin Transl Neurol. 2019;6(2):355–363. Published 2019 Jan 15. PMID: 30847367. Factor de impacto: 3.660.
  • Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18(9):845–856. PMID: 31285147. Factor de impacto: 30.039.
  • Pérez-Pérez S, Eguia Del Rio P, Domínguez-Mozo MI, et al. Epidemiology of multiple sclerosis and vitamin D levels in Lanzarote, Canary Islands, Spain. PeerJ. 2019; 7:e8235. Published 2019 Dec 18. PMID: 31976164. Factor de impacto: 2.379.
  • De la Peña MJ, Peña IC, García PG, Gavilán ML, Malpica N, Rubio M, González RA, de Vega VM. Early perfusion changes in multiple sclerosis patients as assessed by MRI using arterial spin labeling. Acta Radiol Open. 2019 Dec 30;8(12):2058460119894214. doi: 10.1177/2058460119894214. PMID: 32002192. Factor de impacto: 1.635.

  • Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376:221-234. doi: 10.1056/NEJMoa1601277. PMID: 28002679. Factor de impacto: 74.699.
  • Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. PMID: 28002688. Factor de impacto: 74.699.
  • Domínguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galán V, García-Martínez A, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort. Eur J Clin Invest. 2017; 47: 158-166. PMID: 28036121. Factor de impacto: 3.481.
  • Galan V, Casanova I, Alvarez-Lafuente R, Sanchez-Jimenez M, Garcia-Martinez MA, Dominguez-Mozo MI, Arias-Leal AM, Garcia-Montojo M, Arroyo R. Fingolimod use for the treatment of multiple sclerosis in a clinical practice setting in Madrid. Clinical Neuropharmacology. 2017; 40: 29-33. PMID: 27879549. Factor de impacto: 1.295.
  • Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar LM, Alvarez-Cermeño JC, Fernandez O, Alvarez-Lafuente R, Arroyo R, Castro A. Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017; 4: e321. PMID: 28180139. Factor de impacto: 7.724.
  • Arroyo R, Sempere AP, Ruiz-Beato E, Prefasi D, Carreño A, Roset M, Maurino J. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. BMJ Open 2017;7: e014433. PMID: 28274968. Factor de impacto: 2.496.
  • Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965. PMID: 28556498. Factor de impacto: 9.037.
  • Fernández-Paredes L, Casrouge A, Decalf J, de Andrés C, Villar LM, Pérez de Diego R, Alonso B, Álvarez Cermeño JC, Arroyo R, Tejera-Alhambra M, Navarro J, Oreja-Guevara C, López Trascasa M, Seyfferth A, García Martínez MA, Álvarez Lafuente R, Albert ML, Sánchez-Ramón S. Multimarker risk stratification approach at multiple sclerosis onset. Clin Immunol. 2017; 181: 43-50. PMID: 28578025. Factor de impacto: 3.368.
  • Arroyo González R, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL, Giovannoni G; CARE-MS I and II Investigators. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler. 2017 Sep;23(10):1367-1376. doi: 10.1177/1352458516677589. PMID: 27885061. Factor de impacto: 5.412.
 

Copyright © 2025 Dr. Rafael Arroyo — Ascension WordPress theme by GoDaddy